Alpha-GPC and Plasmalogen Nootropics

medlife发现公司（MLD）开发了一种基于合成的由天然代谢物组成的等离子体原前体的治疗阿尔茨海默病的方法。该药经机体转化为神经元所需的多种质脂质。MLD的plasmalogen修复疗法的临床前评估已接近完成，合成正在扩大规模，以支持FDA IND申请和I期临床试验。与我们的合作者一起，MLD正处于轻度认知障碍患者试验计划的最后阶段。接受浆磷脂原前体治疗的患者能够更有效地向突触间隙释放乙酰胆碱。类似地，基于其作为乙酰胆碱的副交感神经前体的作用，化合物甘油磷酸胆碱（GPC）作为治疗阿尔茨海默病的促智药出售。GPC还作为一种营养药品，临床研究表明它对阿尔茨海默病患者的认知表现有影响。GPC作为磷脂酰胆碱的前体影响脂质代谢率。它的毒性很低，在大多数研究中被高浓度摄入（每天300毫克至1200毫克）。像萨斯喀彻温省贝尔平原的乙醇工厂每年可以生产大约15亿500毫克的剂量。个人用GPC自我治疗阿尔茨海默氏症，他们可能会将这种化合物与其他临床治疗方法（如缩醛磷脂）结合使用。首先确定GPC的质量是有价值的。将来，一旦确定了GPC的纯来源，就可以设计适当的临床试验。目前商业化的GPC制剂是由脂质水解而来的，但从乙醇生产GPC是新的。我们的目标是确定商业GPC的纯度，并将其与乙醇生产的GPC进行比较。我们已经在实验室中制备了GPC浓缩液，并将扩大用乙醇生产GPC的规模。在未来的研究中，我们将确定α - gpc与plasmalogen联合使用是否安全。NSERC ENGAGE计划将在萨斯喀彻温大学的生物处理试验工厂生产约200克GPC。

Med-Life discoveries (MLD) has developed plasmalogen restoration as a therapy for Alzheimer's disease that is based on a synthetic plasmalogen precursor composed of naturally occurring metabolites. The drug is converted by the body into a variety of plasmalogen lipid species required by neurons. Preclinical evaluation of MLD's plasmalogen restoration therapy is nearly complete, and synthesis is being scaled up to support an FDA IND submission and a Phase I clinical trial. Together with our collaborators, MLD is in the final stages of planning for trials in patients with mild cognitive impairment. Patients treated with plasmalogen precursors are able to release acetyl choline to the synaptic cleft with greater efficiency. Similarly the compound glycerylphosphorylcholine (GPC) is sold as nootropic for treatment of Alzheimer's disease based on its action as a parasympathomimetic precursor of acetylcholine. GPC also acts as a nutraceutical and clinical studies show its effects on cognitive performance in Alzheimer's patients. GPC affects lipid metabolic rates as it is a precursor to phosphatidyl choline. It is low toxicity and it is consumed at high concentrations (300 mg to 1,200 mg daily) in most studies. An ethanol plant like the one in Belle Plaine, Saskatchewan could produce about 1 billion 500 mg doses per year. Individuals are self treating Alzheimer's with GPC and they might consume this compound in conjunction with other clinical treatments such as plasmalogens. It would be valuable to first determine the GPC quality. In the future, once a pure source of GPC is identified an appropriate clinical trial can be devised. Current commercial GPC preparations arise from lipid hydrolysis but GPC from ethanol production is new. Our goal in this proposal is to determine commercial GPC purity and compare it to GPC from ethanol production. We have prepared GPC concentrates in the laboratory and will scale up GPC production from ethanol. In future research we will determine if alpha-GPC is safe to use in conjunction with plasmalogen. NSERC ENGAGE proposal will conclude with the production of ~200 g of GPC at the University of Saskatchewan's Bioprocessing Pilot Plant.